ContraVir Pharmaceuticals, Inc. (CTRV) Shares Spike on Positive Safety Profile of CMX157
Shares of ContraVir Pharmaceuticals (NASDAQ: CTRV) are trading more than 28% higher in late morning trade after the company said it will pivot from a positive recommendation from an independent Data Safety Monitoring Board (DSMB) to begin enrollment of the next dosing group in its head-to-head phase 2a dose-escalation study. The study is structured to compare the safety and efficacy of ContraVir's CMX157 to tenofovir disoproxil fumarate (TDF, marketed by Gilead Sciences as Viread®) in patients with chronic hepatitis B (HBV). ContraVir expects to complete the remaining two escalation cohorts and report top-line results by year-end 2016. To view the…